Company Overview and News
BOSTON, Feb. 23, 2017 /PRNewswire/ -- Visiomed, the French leader in medical grade connected devices and services since 1997, is changing the landscape of healthcare with their innovative use of modern technology providing patients with pro-active, custom-made solutions. Recognizing the rising demand of self-monitoring alongside the desire for instant and affordable healthcare without walls, Visiomed has launched BewellConnect, the most ground-breaking ecosystem of high-level devices developed with healthcare professionals that is empowering the lives of patients.
PARIS, Jan. 5, 2017 /PRNewswire/ -- VISIOMED Group, a company specialising in next-generation medical electronics, is continuing with its strategic-partnership policy on the annual Consumer Electronics Show (CES) in Las Vegas, with the integration of BewellConnect® connected healthcare services and MAJORD'HOME connected TV platform dedicated to providing home assistance to the elderly.
PARIS, Jan. 4, 2017 /PRNewswire/ -- Next-generation medical electronics specialist VISIOMED GROUP (FR0011067669 ALVMG) announces a partnership with ROBOTOPI at CES Las Vegas, with the aim of equipping SoftBank Robotics' life assistant Pepper with BewellConnect® medical devices and health services.
PARIS, Jan. 4, 2017 /PRNewswire/ -- Next-generation medical electronics specialist VISIOMED GROUP (FR0011067669 – ALVMG) announces a partnership with ROBOTOPI at CES Las Vegas, with the aim of equipping SoftBank Robotics' life assistant Pepper with BewellConnect® medical devices and health services.
2018-04-25 - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
2018-04-25 - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...